APOLLO Oncology Clinical Trials Program
The APOLLO Oncology Clinical Trials Program is a series of trials evaluating and investigating whether Apollomics’ proprietary assets can work in concert with each other or with other agents to improve single agent immunotherapy response rates, and, ultimately, to confer clinical benefit to patients with cancer.
APOLLO Trial
APOLLO is a Phase 1/2, open label, two-arm, multi-center dose escalation and expansion study targeting locally advanced or metastatic disease.
clinicaltrials.gov: NCT03655613
Agents: APL-101 (c-Met inhibitor) + APL-501 (anti-PD-1)
Indication: Hepatocellular Carcinoma
Agents: APL-101 (c-Met inhibitor) + nivolumab (anti-PD-1)
Indication: Renal Cell Carcinoma
APOLLO-2 Trial
APOLLO-2 is a planned clinical trial combining two Apollomics agents: APL-101 and APL-103.
Agents: APL-101 (c-Met inhibitor) + APL-103 (epidermal growth factor receptor inhibitor)
Indication: NSCLC
